Status:
COMPLETED
A Study of Tirzepatide in Overweight and Very Overweight Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tir...
Eligibility Criteria
Inclusion
- Have stable body weight for the past 1 month prior to screening
- Have a body mass index (BMI) between 27 to 50 kilograms per meter squared (kg/m²), inclusive at screening
- Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff
- Women must not be pregnant or breastfeeding
Exclusion
- Have undergone or plan to undergo gastric bypass or bariatric surgery
- Have claustrophobia or have ferromagnetic implants that can interfere with completion of fMRI measurements
- Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study
- Unwilling to comply with smoking and alcohol restrictions during the study
- Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
- Have a diagnosis of type 2 diabetes
Key Trial Info
Start Date :
August 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2022
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04311411
Start Date
August 24 2020
End Date
December 16 2022
Last Update
May 22 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
2
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
3
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287